Donner Corp. International Reiterates Speculative Buy Recommendation on PLC Medical Systems, Inc.


SANTA ANA, Calif., December 20, 2000 (PRIMEZONE) --Donner Corp. International, a broker/dealer specializing in investment banking and headquartered in Santa Ana, Calif., today reiterated its Speculative Buy Recommendation on PLC Medical Systems, Inc. (AMEX:PLC), Franklin, Mass., and issued an updated analyst report. PLC Medical Systems markets a patented high-powered carbon dioxide laser system known as The Heart Laser(TM) System designed for use in the treatment of coronary artery disease in a surgical laser procedure pioneered by the Company known as transmyocardial revascularization (TMR).

"This is a completely new medical treatment option for patients who suffer from severe coronary artery disease," Donner said. "Eighty thousand patients each year who suffer from severe coronary artery disease but cannot be treated with conventional coronary revascularization techniques such as bypass surgery or angioplasty are candidates for TMR."

Donner said that the system has been approved by the U.S. Food and Drug Administration, is reimbursed by Medicare, and has already helped more than 6,500 patients. Popular Science Magazine recently honored PLC Medical Systems with "The Best of What's New for Science and Technology Award," recognition of the high-powered laser that the Company has brought to the medical marketplace, Donner said.

"TMR can significantly reduce angina symptoms, create bloodlines to areas of the heart that cannot be reached by bypass or angioplasty, and has been clinically proven to show long-term pain relief," Donner said. It cited a New England Journal of Medicine report saying TMR has shown a significantly better outcome with respect to improvement in angina, survival free of cardiac events, and freedom from cardiac-related rehospitalization.

"We believe PLC's stock is undervalued considering the proven superiority of the Heart Laser(TM) System over competing laser systems, the growing number of people who will become candidates for TMR treatments using the Heart Laser(TM) System, and increasing industry acceptance of TMR and the Heart Laser(TM) System," Donner concluded.

Copies of the Donner report on PLC Medical Systems, Inc. are available at www.donnercorp.com.

Donner Corp International is a broker member of the National Association of Securities Dealers, CRD 37702. Any information or opinion provided in this report/release does not solicit or make an offer to buy or sell any securities or any options, futures or other derivatives related to such securities herein. DCI and its affiliates may trade for their own accounts in any securities of the issuer or in related securities. DCI or its affiliates, directors, officers and employees, may have a long or short position in securities of the issuer or related investments. DCI or its affiliates may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any entity mentioned in this report/release. This research report/release has been prepared for general circulation and is circulated for general information only. It does not have regard to the specific investment objective, financial situation, suitability, and the particular need of any specific person who may receive this report/release. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in this report/release and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities, if any, may fluctuate and that each security's price or value may rise or fall substantially. Accordingly, investors may receive back less than originally invested. Past performance is not indicative of future performance. Copyright 2000 DCI. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that DCI was recently compensated by PLC in the form of a $2,000 due diligence fee, and DCI receives $500 per month for services provided.



            

Coordonnées